Develops
drugs to block disease promoting actions of white blood cells,
with potential applications within the areas of cancer, autoimmune
and viral diseases.
Stage of Initial
Investment:
Late Stage
Liquidity:
Acquired by Millennium Pharmaceuticals (Nasdaq: MLNM)
